Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High By: Investor Brand Network April 15, 2024 at 09:55 AM EDT Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial. Rezolute, Inc. share prices have moved between a 52-week high of $3.2 and a 52-week low of $0.72. The stock has moved 8% over the past week. To learn more about Rezolute, Inc., visit the company’s website at https://www.rezolutebio.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High By: Investor Brand Network April 15, 2024 at 09:55 AM EDT Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial. Rezolute, Inc. share prices have moved between a 52-week high of $3.2 and a 52-week low of $0.72. The stock has moved 8% over the past week. To learn more about Rezolute, Inc., visit the company’s website at https://www.rezolutebio.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial. Rezolute, Inc. share prices have moved between a 52-week high of $3.2 and a 52-week low of $0.72. The stock has moved 8% over the past week. To learn more about Rezolute, Inc., visit the company’s website at https://www.rezolutebio.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
